galafold
November 15, 2023

Galafold to treat Fabry Disease

Galafold, with the generic name migalastat, stands as a beacon of innovation in the realm of pr…

Vyondys 53
November 15, 2023

All about Vyondys 53

In the ever-evolving landscape of medical advancements, Vyondys 53 has emerged as a notable pla…

viltepso
October 27, 2023

Viltepso (Viltolarsen) for Duchenne Muscular Dystrophy

Introduction Duchenne Muscular Dystrophy (DMD) is a rare and debilitating genetic disorder t…

Oxlumo
October 27, 2023

Oxlumo: Advancing PH1 Treatment With Targeted Therapy

Introduction Oxlumo belongs to the class known as RNAi Agents with an active ingredient call…

Diacomit
October 27, 2023

Diacomit: A Breakthrough For Dravet Syndrome Treatment

Introduction In July of this year, the U.S. Food and Drug Administration (FDA) extended the …

trikafta
October 27, 2023

Trikafta (elexacaftor, tezacaftor, and ivacaftor tablets; ivacaftor tablets): For Cystic Fibrosis

Introduction Trikafta is a groundbreaking medication that received initial approval from the…

venclexta
October 26, 2023

Venclexta (Venetoclax): Pioneering Leukemia Treatment

Introduction Leukemia, a formidable adversary, has met its match in Venclexta (Venetoclax). …

Adcetris
October 26, 2023

Adcetris: Treats Hodgkin lymphoma and a Rare Lymphoma

Adcetris (brentuximab vedotin) is a medication used to treat Hodgkin lymphoma and a rare lympho…

Atriance
October 26, 2023

Atriance (Nelarabine) to treat Acute Lymphoblastic Leukemia

Introduction Atriance ((Nelarabine) has received approval from the for the treatment of acut…

Sarclisa
October 26, 2023

All about Sarclisa

Introduction Sarclisa, with its active ingredient, Isatuximab-irfc, is a significant advance…

Monjuvi
October 26, 2023

Monjuvi (Tafasitamab): A Therapeutic Breakthrough in DLBCL

Introduction Tafasitamab, a CD19-targeted cytolytic antibody, has received FDA accelerated a…

Retevmo
October 26, 2023

Retevmo: A Breakthrough Medication For Advanced Cancers

Retevmo (Selpercatinib) is a medication used to treat certain advanced cancers that test positi…

October 26, 2023

All about Trodelvy

Trodelvy (sacituzumab govitecan-hziy) was approved by the US Food and Drug Administration (FDA)…

Piqray
October 18, 2023

Piqray: Advanced HR+/HER2 Breast Cancer Novel Treatment.

In a significant development for advanced breast cancer treatment, Alpelisib Novartis received …

welireg
October 18, 2023

Belzutifan: Advanced Cancer Therapy with Promising Potential

On August 13, 2021, the Food and Drug Administration (FDA) granted approval for Belzutifan, mar…

×